20210310 Transgene TG4001 randomized Phase II EN
Category: TG4001
Correlation of HPV16 Gene Status and Gene Expression With Antibody Seropositivity and TIL Status in OPSCC
Adrian von Witzleben, et al. Front Oncol., January 26 2021 – Read the article Publication
Transgene to present Phase 1b/2 trial results of TG4001 in combination with avelumab in advanced HPV-positive cancers at ESMO IO 2020
20201203 – TG4001 mini oral prez ESMO IO EN
Transgene presents e-poster outlining detailed results from the Phase 1b/2 trial of TG4001 in combination with avelumab in advanced HPV-positive cancers at SITC 2020
20201109 – TG4001+avelumab presentation poster SITC – EN
TG4001 (Tipapkinogene sovacivec) and avelumab for recurrent/metastatic (R/M) Human Papilloma Virus (HPV)-16+ cancers: clinical efficacy and immunogenicity
Poster SITC TG4001 C. Le Tourneau et al. SITC 2020 Download the poster here Poster Presentation
Transgene announces detailed results from clinical study of TG4001 in combination with avelumab in advanced HPV-positive cancers
20201027 – TG4001+avelumab abstract data SITC – EN
Acceptance of Late Breaking Abstract at Upcoming SITC 2020 Conference, on the detailed results from clinical study of TG4001 in combination with avelumab in advanced HPV-positive cancers
20201019 TG4001+avelumab SITC – EN
Transgene Reports Results from Clinical Study of TG4001 in Combination with Avelumab in Advanced HPV-Positive Cancers
CP TG4001+avelumab EN – Vdef-
Transgene Reports First Promising Efficacy Results with TG4001 in Combination with Avelumab in HPV-Positive Cancer at ESMO 2019
20190930 PR TG4001 ESMO EN
Phase Ib/II trial of TG4001 (Tipapkinogene sovacivec), a therapeutic HPV-vaccine, and Avelumab in patients with recurrent/metastatic HPV16 positive cancers
Christophe Le Tourneau et al. ESMO 2019 Download the poster here Poster Presentation
